Agile Therapeutics Announces Full Exercise of Over-Allotment Option by Underwriters
August 08 2019 - 4:15PM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare
company, today announced that the underwriters of its previously
announced public offering of common stock have exercised in full
their option to purchase an additional 1,894,736 shares of Agile
Therapeutics’ common stock. The additional shares were sold at the
public offering price of $0.95 per share, before underwriting
discounts and commissions. The closing occurred on August 8, 2019,
bringing the total number of shares sold by Agile Therapeutics in
the public offering to 14,526,315 and total gross proceeds to
approximately $13.8 million. The total net proceeds, after
deducting underwriting discounts and commissions and estimated
offering expenses, are expected to be approximately $12.6 million
from the offering.
Oppenheimer & Co. Inc. acted as the sole
book-running manager for the offering. H.C. Wainwright &
Co., LLC acted as lead manager for the offering.
The shares of common stock described above were
offered by Agile Therapeutics pursuant to its shelf registration
statement on Form S-3 previously filed and declared effective by
the Securities and Exchange Commission. The offering has been
made only by means of a prospectus supplement and the accompanying
prospectus, copies of which may be obtained from Oppenheimer &
Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St.,
26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or
by email at EquityProspectus@opco.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Agile Therapeutics,
Inc.Agile Therapeutics is a forward-thinking women's
healthcare company dedicated to fulfilling the unmet health needs
of today’s women. Our product candidates are designed to
provide women with contraceptive options that offer freedom from
taking a daily pill, without committing to a longer-acting
method. Our lead product candidate, Twirla®, (ethinyl
estradiol and levonorgestrel transdermal system), also known as
AG200-15, is an investigational low-dose, non-daily prescription
contraceptive. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to allow drug
delivery through the skin. For more information, please visit the
company website at www.agiletherapeutics.com. The Company may
occasionally disseminate material, nonpublic information on the
Company’s website.
Forward-Looking Statement
Certain information contained in this press
release includes "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to our public offering and potential market
opportunity for our product candidates. We may, in some cases, use
terms such as "predicts," "believes," "potential," "continue,"
"anticipates," "estimates," "expects," "plans," "intends," "may,"
"could," “might," "will," "should" or other words that convey
uncertainty of the future events or outcomes to identify these
forward-looking statements. Our forward-looking statements are
based on current expectations that involve risks, potential changes
in circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or, be
affected by inaccurate assumptions we might make or by known or
unknown risks and uncertainties as a result of various important
factors, including the uncertainties related to market conditions
and such other factors. For a more detailed description of
the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to our business in general, please refer to
our prospectus supplement filed with the Securities and Exchange
Commission (SEC) on August 2, 2019 under the heading “Risk Factors”
and those documents incorporated by reference therein, which
includes our Annual Report on Form 10-K and our Quarterly Reports
on Form 10-Q. You are cautioned not to place undue reliance on
these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Source: Agile Therapeutics
Contact: Investor Relations --
609-683-1880
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024